Acute Ischemic Stroke Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight

"Acute Ischemic Stroke Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Acute Ischemic Stroke Therapeutics Market. As per DelveInsight's assessment, globally, about 35+ key pharma and biotech companies are working on 35+ pipeline drugs in the Acute Ischemic Stroke therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The report provides a detailed description of the Acute Ischemic Stroke drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Acute Ischemic Stroke Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Acute Ischemic Stroke Pipeline Report
• Acute Ischemic Stroke companies working in the treatment market are Acticor Biotech, Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others, are developing therapies for the Acute Ischemic Stroke treatment
• Emerging Acute Ischemic Stroke therapies in the different phases of clinical trials are- ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS007), 3K3A-APC, Nerinetide, Nelonemdaz, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.
• In May 2025, Results from the randomized ASSET-IT trial suggest that adding intravenous (IV) tirofiban to standard systemic thrombolysis within 4.5 hours of acute ischemic stroke onset enhances functional outcomes. An excellent recovery-defined as a modified Rankin Scale (mRS) score of 0-1-was seen in 65.9% of patients receiving tirofiban, compared to 54.9% in the placebo group (adjusted risk ratio 1.18; 95% CI: 1.06-1.31). Although there were more cases of symptomatic intracranial hemorrhage in the tirofiban group (seven vs. none), the overall incidence remained low at 1.7%.
• In February 2025, Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced plans to present new clinical findings from its ongoing HEMERA-1 Phase 1 trial focused on acute ischemic stroke (AIS). The poster presentation will feature updates on the company's lead candidate, PP-007, a PEGylated carboxyhemoglobin bovine therapy. Prolong recently concluded enrollment for Part 3 of the trial, representing a significant milestone in the development of the AIS program.
• In February 2025, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel therapies for severe ischemic conditions, has announced the peer-reviewed publication of a study titled "Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence" by Kasner et al. The study is currently available online and will be featured in the February 2025 edition of the journal Stroke.
• In November 2024:- Shanghai Hutchison Pharmaceuticals Limited- This study is a Phase II, multicenter, randomized, double Blind, placebo-Controlled design. Participants receive twice daily dosing for 7 consecutive days, or once on Days 1 and Day 8 and twice daily on Days 2 to Day 7, with each subject scheduled to receive 14 doses throughout the clinical trial. 270 Participants will be randomized 1:1:1 to SHPL-49 injection treated group (3 ampoules of SHPL-49 injections, BID), SHPL-49 injection treated group (6 ampoules of SHPL-49 injections , BID) and placebo group (BID).
• DelveInsight's Acute Ischemic Stroke pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Acute Ischemic Stroke treatment.
• The leading Acute Ischemic Stroke Companies such as Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others.
• Promising Acute Ischemic Stroke therapies such as Sovateltide, Tenecteplase, BB-031, hUCB, LT3001, Elezanumab, Redasemtide, Cerebrolysin, SP-8203 , and others.

Acute Ischemic Stroke Overview
Acute Ischemic Stroke (AIS) occurs when blood flow to a part of the brain is blocked, usually due to a thrombus or embolus obstructing a cerebral artery. This lack of oxygen and nutrients leads to rapid brain cell death and neurological deficits. AIS accounts for nearly 85% of all stroke cases worldwide, making it a leading cause of disability and mortality.
Risk factors include hypertension, diabetes, obesity, atrial fibrillation, smoking, and aging populations. The condition is a medical emergency requiring immediate intervention to restore perfusion and minimize brain damage. Current treatment approaches involve intravenous thrombolysis (tPA within 4.5 hours) and mechanical thrombectomy (within 6-24 hours) for eligible patients.
Ongoing research focuses on expanding treatment windows, neuroprotective therapies, advanced imaging for patient selection, and novel antithrombotic strategies. Despite progress, challenges such as delayed diagnosis, limited access to specialized care, and post-stroke disability remain significant barriers.

Learn More about the Clinical and Commercial Development Activities in the Acute Ischemic Stroke Therapeutics Domain @ https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute Ischemic Stroke Therapeutics Analysis
Over 35+ pharma and biotech companies are actively involved in the development of therapies for Acute Ischemic Stroke. Notably, GNT Pharma stands out among them, with Acute Ischemic Stroke drug candidates progressing to the most advanced stage, namely phase III of clinical trials. The diverse landscape of companies reflects the collective dedication to advancing innovative solutions for Acute Ischemic Stroke and underscores the promising advancements in the field of treatment for this medical condition.

What Are the Emerging Drugs for Acute Ischemic Stroke (AIS)?
Prourokinase Recombinant (Tasly Pharmaceutical)
A novel thrombolytic that selectively activates plasminogen on fibrin, offering potent clot lysis with fewer side effects compared to existing therapies. It is currently in Phase III trials.
RNS60 (Revalesio Corporation)
A neuroprotective agent that enhances mitochondrial function, reduces inflammation, and restores neuronal homeostasis. It has FDA Orphan Drug and Fast Track designations for ALS and is in Phase II development for AIS.
AVLX-144 (Avilex Pharma)
A dimeric PSD-95 inhibitor designed to block excitotoxicity and provide neuroprotection. Its unique structure improves affinity, stability, and efficacy. The drug is currently in Phase I trials.

Acute Ischemic Stroke Companies in the Therapeutics Market Include:
Some of the key companies in the Acute Ischemic Stroke Market include Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, NuvOx Pharma, Healios, Acticor Biotech, Biogen, ZZ Biotech, Revalesio Corporation, Shionogi & Co., Ltd., AbbVie, Pharming Group, Bristol-Myers Squibb, Roche, Clinuvel Pharmaceuticals, TrueBinding, ShinPoong Pharmaceutical, Lumosa Therapeutics, NC Medical Research, JCR Pharmaceuticals, aptaTargets, PT. Prodia Stem Cell Indonesia, and many others.

Emerging and Marketed Acute Ischemic Stroke Therapies Covered in the Report Include:
• Nelonemdaz: GNT Pharma
• Tenecteplase: Genentech
• SP-8203: Shin Poong Pharmaceutical
• NONO-SC: NoNO Inc.
• Glenzocimab: Acticor Biotech
• DM199: DiaMedica Therapeutics
• LT3001: Lumosa Therapeutics
• Nerinetide: NoNO Inc.
• BMS-986177/milvexian: Bristol Myers Squibb Company/Janssen Pharmaceuticals
• Invimestrocel: Healios/Athersys
And Many More

Get an in-depth Assessment of the Emerging Therapies and Acute Ischemic Stroke Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Acute Ischemic Stroke Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Acute Ischemic Stroke Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Request for Sample PDF to Understand More About the Acute Ischemic Stroke Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.